Hemaclear Announces First Annual Italian Distributor and User Conference: May 22, 2013 in Rome, Italy
OHK Medical Devices Ltd., manufacturer of the HemaClear® single-use, sterile, exsanguinating tourniquet device, announced today that it will hold its first annual Italian distributor and user conference; May 22, 2013 in Rome, Italy.
Haifa, Israel (PRWEB) May 15, 2013
OHK Medical Devices Ltd., manufacturer of the HemaClear® single-use, sterile exsanguinating tourniquet device, announced today that it will hold its first annual Italian distributor and user conference; May 22, 2013 in Rome, Italy. The conference will be the first time Hemaclear users and distributors from Italy will meet to discuss the competitive and clinical advantage of the novel tourniquet.
Since the launch of Hemaclear in 2008 in Italy, the novel tourniquet has quickly become the standard of care at many Italian hospitals and clinics. Over the past 5 years regional distributors have recognized the positive business contributions of the device, while surgeons have recognized the positive clinical contributions. In a country where reusable pneumatic tourniquets were the standard of care prior to the launch of Hemaclear, physicians and patients can now experience the benefits of a reliable, safe, and sterile tourniquet.
“We are very excited to have the opportunity to meet with our distributor partners and surgeon users in Rome. This conference will provide all an opportunity to learn, network, and further discuss our commercialization efforts in Italy,” said Omer Inbar, CEO, OHK Medical Devices. Mr. Inbar added, “After a very strong year in 2012, we hope to continue the positive momentum in Italy. We strive to increase our Italian distribution network, and surgeon user base.”
OHK Medical Devices will be hosting the meeting May 22, 2013 at the Sofitel Rome Villa Borghese. To schedule a meeting or learn more about the conference please email info(at)hemaclear(dot)com.
HemaClear® is the world´s leading sterile tourniquet with a simple yet innovative technology, representing a new standard of care in bloodless orthopedic surgery. Since entering the market in 2007 this product has been successfully used in almost 500,000 procedures. Easier, cheaper and safer than the standard offerings, HemaClear® represents the first significant advancement in tourniquet technology in over 100 years. HemaClear® was developed by OHK Medical Devices (OHK), a privately held company based in Haifa, Israel and the United States and is currently used in over 2000 operating rooms across 30 countries. For more information about HemaClear®, visit http://www.hemaclear.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/5/prweb10735331.htm